|

Zhejiang Jingxin Pharmaceutical Co received the "Drug Registration Certificate" for the first-class innovative drug Dadasini Capsules on Dec 5.

"The moment we received the approval for the company's first innovative drug, everyone felt relieved and full of anticipation," said Zhang Linhai, director of the company's formulation institute, wearing a rare radiant smile.

The development of Dadasini began in 2010, with Jingxin Pharmaceutical investing significant research and development funds and resources.

The drug is primarily designed for the short-term treatment of insomnia patients, demonstrating remarkable efficacy in clinical trials while ensuring safety and therapeutic benefits.

According to the "2022 China National Health Sleep White Paper," over 300 million people in China suffered from sleep disorders in 2021, with an insomnia incidence rate among adults reaching 38.2 percent. The awareness of sleep disorders and targeted treatment is urgently needed.

The market debut of this drug provides a new therapeutic option for individuals grappling with insomnia disorders, filling a longstanding void in the domestic market for new insomnia drugs. It is expected to propel Jingxin Pharmaceutical into a new phase of development focused on the integration of mental health and innovation.

Zhejiang Jingxin Pharmaceutical Co is a pharmaceutical listed company that integrates research and development, production, and sales, with a commitment to becoming a leader in the Chinese fields of mental health and cardiovascular diseases.